These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

839 related articles for article (PubMed ID: 27989218)

  • 1. The Safety of available immunotherapy for the treatment of glioblastoma.
    Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
    Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
    Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
    Trials; 2018 May; 19(1):293. PubMed ID: 29801515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in Immunotherapy for Glioblastoma Multiforme.
    Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
    J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook.
    Gedeon PC; Champion CD; Rhodin KE; Woroniecka K; Kemeny HR; Bramall AN; Bernstock JD; Choi BD; Sampson JH
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1147-1158. PubMed ID: 32862726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current vaccine trials in glioblastoma: a review.
    Xu LW; Chow KK; Lim M; Li G
    J Immunol Res; 2014; 2014():796856. PubMed ID: 24804271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promising vaccines for treating glioblastoma.
    Swartz AM; Shen SH; Salgado MA; Congdon KL; Sanchez-Perez L
    Expert Opin Biol Ther; 2018 Nov; 18(11):1159-1170. PubMed ID: 30281978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current challenges in designing GBM trials for immunotherapy.
    Weathers SP; Gilbert MR
    J Neurooncol; 2015 Jul; 123(3):331-7. PubMed ID: 25577401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing immunotherapeutic strategies to target brain tumors.
    Lieberman NA; Moyes KW; Crane CA
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):775-88. PubMed ID: 27253692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
    Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
    Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospects of immune checkpoint modulators in the treatment of glioblastoma.
    Preusser M; Lim M; Hafler DA; Reardon DA; Sampson JH
    Nat Rev Neurol; 2015 Sep; 11(9):504-14. PubMed ID: 26260659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glioblastoma stem cells and stem cell-targeting immunotherapies.
    Esparza R; Azad TD; Feroze AH; Mitra SS; Cheshier SH
    J Neurooncol; 2015 Jul; 123(3):449-57. PubMed ID: 25682090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope?
    Ferguson SD; Srinivasan VM; Ghali MG; Heimberger AB
    Immunotherapy; 2016; 8(4):413-23. PubMed ID: 26973123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New perspectives in glioma immunotherapy.
    Daga A; Bottino C; Castriconi R; Gangemi R; Ferrini S
    Curr Pharm Des; 2011; 17(23):2439-67. PubMed ID: 21827420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune and viral therapies for malignant primary brain tumors.
    Gardeck AM; Sheehan J; Low WC
    Expert Opin Biol Ther; 2017 Apr; 17(4):457-474. PubMed ID: 28274139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.
    Swartz AM; Li QJ; Sampson JH
    Immunotherapy; 2014; 6(6):679-90. PubMed ID: 25186601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
    Londhe VY; Date V
    Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological Aspects of Malignant Gliomas.
    Cohen-Inbar O; Zaaroor M
    Can J Neurol Sci; 2016 Jul; 43(4):494-502. PubMed ID: 27324313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.